Understand the source comparison
SS-LUP-332 Side Effects: Study Comparison
Phase I (Colorado) 8 weeks 48 healthy adults Injection site reactions (22%), nausea (12%), headache (6%) 0% None reported Tolerability matches other selective peptide modulators. No dose-limiting toxicity identified Preclinical (rodent) 16 weeks 60 Sprague-Daw
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Phase I (Colorado)
- 8 weeks
- 48 healthy adults
- Injection site reactions (22%), nausea (12%), headache (6%)
- 0%
- None reported
- Tolerability matches other selective peptide modulators. No dose-limiting toxicity identified
- Preclinical (rodent)
- 16 weeks
- 60 Sprague-Dawley rats
- Weight loss (dose-dependent), transient ALT elevation at 50mg/kg (resolved by week 8)
- N/A
- None
- High-dose hepatic stress reversed upon dose reduction. Human equivalent dose far exceeds clinical range
- Phase Ib (metabolic cohort)
- 12 weeks
- 32 adults with BMI 28–35
- Mild nausea (9%), injection site erythema (19%), no hypoglycemia
- 3% (unrelated to adverse events)
- Metabolic endpoints (HbA1c, fasting insulin) improved without safety signals. Longer trials needed for NAFLD assessment